Bio-Rad reports Q1 EPS $1.89, consensus $1.99

Reports Q1 revenue $592.1M, consensus $588.86M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and CEO, stated: “Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite external headwinds including challenging academic end markets and conflict escalation in the Middle East, reported sales grew 1.1% year-over-year. Against this backdrop, we generated strong operating cash flow, $78 million in free cash flow, and repurchased approximately 176 thousand shares, highlighting the quality and long-term durability of our business. We continue to evaluate and optimize our organization to create more value for customers, and ultimately, shareholders.”